Financhill
Sell
43

CLLS Quote, Financials, Valuation and Earnings

Last price:
$1.85
Seasonality move :
-14.06%
Day range:
$1.88 - $2.03
52-week range:
$1.41 - $3.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.95x
P/B ratio:
1.49x
Volume:
196.7K
Avg. volume:
147.5K
1-year change:
-35.88%
Market cap:
$193.2M
Revenue:
$755K
EPS (TTM):
-$1.34

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CLLS
Cellectis SA
$21.5M -$0.21 3346.52% -69.12% $6.67
AKTX
Akari Therapeutics PLC
-- -- -- -- --
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.97
DBVT
DBV Technologies SA
$1.1M -$0.22 -- -59.89% $22.11
EDAP
Edap TMS SA
$20.8M -$0.11 -1.4% -21.79% $10.67
GNFT
Genfit SA
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CLLS
Cellectis SA
$1.93 $6.67 $193.2M -- $0.00 0% 5.95x
AKTX
Akari Therapeutics PLC
$1.28 -- $31.7M -- $0.00 0% --
BDRX
Biodexa Pharmaceuticals PLC
$4.27 $17.97 $2.5M -- $0.00 0% 3.85x
DBVT
DBV Technologies SA
$3.83 $22.11 $78.6M -- $0.00 0% --
EDAP
Edap TMS SA
$2.20 $10.67 $81.6M -- $0.00 0% 1.19x
GNFT
Genfit SA
$3.67 -- $183.2M 32.57x $0.00 0% 2.66x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CLLS
Cellectis SA
26.36% 1.043 21.83% 1.74x
AKTX
Akari Therapeutics PLC
-- -0.056 -- --
BDRX
Biodexa Pharmaceuticals PLC
-- 0.100 -- 1.20x
DBVT
DBV Technologies SA
-- -0.335 -- --
EDAP
Edap TMS SA
8.17% -1.064 4.48% 1.42x
GNFT
Genfit SA
-- 0.097 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CLLS
Cellectis SA
-- -$10.8M -57.78% -79.78% -130.83% -$6.6M
AKTX
Akari Therapeutics PLC
-- -$1.9M -- -- -- -$1.5M
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
DBVT
DBV Technologies SA
-- -$30.3M -- -- -- -$22.9M
EDAP
Edap TMS SA
$5.7M -$6.4M -39.29% -42.5% -44.53% -$6.7M
GNFT
Genfit SA
-- -- -- -- -- --

Cellectis SA vs. Competitors

  • Which has Higher Returns CLLS or AKTX?

    Akari Therapeutics PLC has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
    AKTX
    Akari Therapeutics PLC
    -- -$0.24 --
  • What do Analysts Say About CLLS or AKTX?

    Cellectis SA has a consensus price target of $6.67, signalling upside risk potential of 245.42%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 6150%. Given that Akari Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics PLC is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    3 1 0
    AKTX
    Akari Therapeutics PLC
    0 0 0
  • Is CLLS or AKTX More Risky?

    Cellectis SA has a beta of 3.082, which suggesting that the stock is 208.158% more volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.789, suggesting its less volatile than the S&P 500 by 21.114%.

  • Which is a Better Dividend Stock CLLS or AKTX?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or AKTX?

    Cellectis SA quarterly revenues are $16.2M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Cellectis SA's net income of -$23.1M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Cellectis SA's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 5.95x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    5.95x -- $16.2M -$23.1M
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$2.9M
  • Which has Higher Returns CLLS or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About CLLS or BDRX?

    Cellectis SA has a consensus price target of $6.67, signalling upside risk potential of 245.42%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 320.87%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Cellectis SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    3 1 0
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is CLLS or BDRX More Risky?

    Cellectis SA has a beta of 3.082, which suggesting that the stock is 208.158% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.

  • Which is a Better Dividend Stock CLLS or BDRX?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or BDRX?

    Cellectis SA quarterly revenues are $16.2M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Cellectis SA's net income of -$23.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 5.95x versus 3.85x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    5.95x -- $16.2M -$23.1M
    BDRX
    Biodexa Pharmaceuticals PLC
    3.85x -- -- --
  • Which has Higher Returns CLLS or DBVT?

    DBV Technologies SA has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
    DBVT
    DBV Technologies SA
    -- -$1.60 --
  • What do Analysts Say About CLLS or DBVT?

    Cellectis SA has a consensus price target of $6.67, signalling upside risk potential of 245.42%. On the other hand DBV Technologies SA has an analysts' consensus of $22.11 which suggests that it could grow by 474.73%. Given that DBV Technologies SA has higher upside potential than Cellectis SA, analysts believe DBV Technologies SA is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    3 1 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is CLLS or DBVT More Risky?

    Cellectis SA has a beta of 3.082, which suggesting that the stock is 208.158% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.023%.

  • Which is a Better Dividend Stock CLLS or DBVT?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or DBVT?

    Cellectis SA quarterly revenues are $16.2M, which are larger than DBV Technologies SA quarterly revenues of --. Cellectis SA's net income of -$23.1M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Cellectis SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 5.95x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    5.95x -- $16.2M -$23.1M
    DBVT
    DBV Technologies SA
    -- -- -- -$30.4M
  • Which has Higher Returns CLLS or EDAP?

    Edap TMS SA has a net margin of -142.32% compared to Cellectis SA's net margin of -48.85%. Cellectis SA's return on equity of -79.78% beat Edap TMS SA's return on equity of -42.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
  • What do Analysts Say About CLLS or EDAP?

    Cellectis SA has a consensus price target of $6.67, signalling upside risk potential of 245.42%. On the other hand Edap TMS SA has an analysts' consensus of $10.67 which suggests that it could grow by 384.85%. Given that Edap TMS SA has higher upside potential than Cellectis SA, analysts believe Edap TMS SA is more attractive than Cellectis SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    3 1 0
    EDAP
    Edap TMS SA
    1 0 0
  • Is CLLS or EDAP More Risky?

    Cellectis SA has a beta of 3.082, which suggesting that the stock is 208.158% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.908%.

  • Which is a Better Dividend Stock CLLS or EDAP?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or EDAP?

    Cellectis SA quarterly revenues are $16.2M, which are larger than Edap TMS SA quarterly revenues of $14.4M. Cellectis SA's net income of -$23.1M is lower than Edap TMS SA's net income of -$7M. Notably, Cellectis SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 5.95x versus 1.19x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    5.95x -- $16.2M -$23.1M
    EDAP
    Edap TMS SA
    1.19x -- $14.4M -$7M
  • Which has Higher Returns CLLS or GNFT?

    Genfit SA has a net margin of -142.32% compared to Cellectis SA's net margin of --. Cellectis SA's return on equity of -79.78% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CLLS
    Cellectis SA
    -- -$0.23 $175.7M
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About CLLS or GNFT?

    Cellectis SA has a consensus price target of $6.67, signalling upside risk potential of 245.42%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 180.13%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    CLLS
    Cellectis SA
    3 1 0
    GNFT
    Genfit SA
    0 0 0
  • Is CLLS or GNFT More Risky?

    Cellectis SA has a beta of 3.082, which suggesting that the stock is 208.158% more volatile than S&P 500. In comparison Genfit SA has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.46%.

  • Which is a Better Dividend Stock CLLS or GNFT?

    Cellectis SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectis SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CLLS or GNFT?

    Cellectis SA quarterly revenues are $16.2M, which are larger than Genfit SA quarterly revenues of --. Cellectis SA's net income of -$23.1M is higher than Genfit SA's net income of --. Notably, Cellectis SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectis SA is 5.95x versus 2.66x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CLLS
    Cellectis SA
    5.95x -- $16.2M -$23.1M
    GNFT
    Genfit SA
    2.66x 32.57x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is ARK Next Generation Internet ETF a Good Investment?
Is ARK Next Generation Internet ETF a Good Investment?

The ARK Next Generation Internet ETF looks like a pretty…

Why Is Marvell Stock Up?
Why Is Marvell Stock Up?

Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…

Why Is General Electric Stock Going Up?
Why Is General Electric Stock Going Up?

General Electric Company, doing business these days as GE Aerospace…

Stock Ideas

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Sell
44
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
1
IONQ alert for Jan 10

IonQ [IONQ] is up 7.07% over the past day.

Sell
47
CEG alert for Jan 10

Constellation Energy [CEG] is up 25.15% over the past day.

Sell
8
CRNX alert for Jan 10

Crinetics Pharmaceuticals [CRNX] is down 16.31% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock